1. Home
  2. ETS vs TPST Comparison

ETS vs TPST Comparison

Compare ETS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ETS

Elite Express Holding Inc.

BUY

Current Price

$2.44

Market Cap

96.7M

Sector

Industrials

ML Signal

BUY

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

BUY

Current Price

$0.51

Market Cap

13.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ETS
TPST
Founded
2020
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.7M
13.7M
IPO Year
2025
2012

Fundamental Metrics

Financial Performance
Metric
ETS
TPST
Price
$2.44
$0.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
45.3K
★ 281.5K
Earning Date
10-14-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $2,665,948.00
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 21.57
N/A
52 Week Low
$0.39
$0.52
52 Week High
$2.75
$11.13

Technical Indicators

Market Signals
Indicator
ETS
TPST
Relative Strength Index (RSI) 68.71 27.11
Support Level $0.47 N/A
Resistance Level $2.75 $1.24
Average True Range (ATR) 0.25 0.05
MACD 0.05 -0.02
Stochastic Oscillator 89.09 2.12

Price Performance

Historical Comparison
ETS
TPST

About ETS Elite Express Holding Inc.

Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: